Mylotarg (Wyeth) en es it fr

Mylotarg (Wyeth) Brand names, Mylotarg (Wyeth) Analogs

Mylotarg (Wyeth) Brand Names Mixture

  • No information avaliable

Mylotarg (Wyeth) Chemical_Formula

No information avaliable

Mylotarg (Wyeth) RX_link

http://www.rxlist.com/cgi/generic2/gemtuzumab.htm

Mylotarg (Wyeth) fda sheet

Mylotarg (Wyeth) msds (material safety sheet)

Mylotarg (Wyeth) Synthesis Reference

(Sequence listed in CO MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C: Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 148:1149, 1991) (Caron PC, Schwartz MA, Co MS, Queen C, Finn RD, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer. 1994 Feb 1;73(3 Suppl):1049-56)

Mylotarg (Wyeth) Molecular Weight

No information avaliable

Mylotarg (Wyeth) Melting Point

61 oC (FAB fragment), 71 oC (whole mAb)-Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

Mylotarg (Wyeth) H2O Solubility

No information avaliable

Mylotarg (Wyeth) State

Liquid

Mylotarg (Wyeth) LogP

No information avaliable

Mylotarg (Wyeth) Dosage Forms

Solution (IV Infusion)

Mylotarg (Wyeth) Indication

For treatment of acute myeloid leukemia

Mylotarg (Wyeth) Pharmacology

Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cells.

Mylotarg (Wyeth) Absorption

No information avaliable

Mylotarg (Wyeth) side effects and Toxicity

No information avaliable

Mylotarg (Wyeth) Patient Information

No information avaliable

Mylotarg (Wyeth) Organisms Affected

Humans and other mammals